FDA Brief

Warning letters Drugs

FDA warning letter to

Cohere Beauty

MediumIssued Apr 15, 2024Posted May 14, 2024Division of Pharmaceutical Quality Operations IV

FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.

What happened

FDA inspected the drug manufacturing facility from November 27 to 30, 2023, and found that the company had not validated its OTC drug manufacturing process before releasing and distributing multiple lots in 2023. FDA also found that the quality unit failed to ensure analytical methods were validated or verified and did not adequately investigate an out-of-specification result. The letter notes that the company had committed in a June 20, 2023, meeting to stop distribution until test methods were validated and a contract lab was qualified, but it distributed drug lots between June 28 and October 26, 2023, and accepted new purchase orders.

What FDA found

  1. Cohere Beauty did not validate the manufacturing process for an OTC drug product before releasing and distributing multiple lots in 2023.

    21 CFR 211.100(a)
  2. Its quality unit did not ensure analytical test methods were validated or verified and did not adequately investigate an out-of-specification result for a bulk drug product.

    21 CFR 211.22
  3. Despite commitments to stop distribution until test methods were validated and a contract testing laboratory was qualified, the firm released and distributed hand sanitizer and other drug lots and accepted new orders.

    21 CFR 211.22

What FDA wants

FDA tells the company to correct violations promptly and respond in writing within 15 working days, explaining actions taken or a completion schedule. If it resumes drug manufacturing, it must notify FDA and engage a qualified consultant to audit its operation.

Who should pay attention

  • companies that buy OTC drugs from contract manufacturers
  • brands relying on Cohere Beauty for hand sanitizer or other OTC drugs
  • quality teams managing supplier qualification and process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk